Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement

Rhea-AI Summary

Eledon Pharmaceuticals announced an oversubscribed $50 million private placement deal with institutional investors, including BVF Partners LP. The financing involves the sale of common stock and pre-funded warrants at specific prices. The net proceeds will be used for pre-commercial activities and general corporate purposes, including the clinical development of its lead product tegoprubart.

Positive

• Eledon Pharmaceuticals secured $50 million in private placement funding, showing investor confidence in the company's future prospects.

• The financing deal was oversubscribed, indicating strong demand from both new and existing investors, including BVF Partners LP.

• The company plans to utilize the proceeds to fund pre-commercial activities, which includes advancing the clinical development of its lead asset tegoprubart.

• The registration rights agreement with the investors demonstrates transparency and commitment to regulatory compliance.

Negative

• The common shares and pre-funded warrants issued in the private placement are not registered under the Securities Act of 1933, potentially limiting their resale options in the United States.

• There is a risk of regulatory hurdles or delays in the registration process with the Securities and Exchange Commission for the resale of the securities issued in the private placement.

Insights

Financial Analyst

The announcement by Eledon Pharmaceuticals of an oversubscribed private placement generating approximately $50 million indicates a strong investor interest in the company's equity. It's noteworthy that the offering price of $2.37 per share and pre-funded warrants at nearly the same price shows investor confidence despite the potential dilution of shares. The exercise price of $0.001 per share for the warrants is nominal, possibly indicating a favorable future outlook by the investors. The use of proceeds for pre-commercial activities and clinical development of tegoprubart suggests a strategic focus on advancing their lead asset. However, the impact on current shareholders must be scrutinized. On one hand, the capital infusion can accelerate product development and clinical trials, potentially enhancing the company's value. On the other, the issuance of additional shares could lead to share dilution, potentially affecting the stock's price in the short term. The involvement of reputable institutions like BVF Partners LP and the role of established financial firms as placement agents add a layer of credibility to the transaction. Overall, the event could be seen as a positive development given the company's direction, but with a cautionary note on dilution.

Biotech Industry Analyst

From a biotech industry perspective, Eledon Pharmaceuticals' decision to fund pre-commercial activities and the clinical development of lead asset tegoprubart aligns with common practices within the sector. Firms often seek substantial capital to support resource-intensive research and development phases, particularly in the later stages leading up to potential commercialization. The investors' appetite, resulting in an oversubscribed round, is indicative of confidence in Eledon's methodologies and market prospects of tegoprubart. However, the risks inherent in biotech investments, such as regulatory hurdles, clinical trial results and market adoption, must be highlighted. Despite these risks, a successful advancement through clinical trials can lead to significant market opportunities and collaborations, potentially yielding a high return on investment for the participants in the private placement. It's important for investors to monitor the development of tegoprubart closely as it progresses, as these milestones will likely have material effects on the company's valuation and stock performance. The commitment to file a registration statement for reselling the securities suggests a future increase in liquidity, which is generally favorable for investors.

IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it has entered into a securities purchase agreement with certain institutional and accredited healthcare investors for a private investment in public equity financing that is expected to result in gross proceeds of approximately $50 million, before deducting offering expenses. Pursuant to the terms of the securities purchase agreement, Eledon is selling an aggregate of 13,110,484 shares of its common stock ("Common Stock") at a price of $2.37 per share and pre-funded warrants at a price of $2.369 per underlying share, which are exercisable to purchase 7,989,516 shares of Common Stock at a price of $0.001 per share. The financing is expected to close the week of May 6, 2024, subject to satisfaction of customary closing conditions. The oversubscribed financing was led by BVF Partners LP and includes participation from new and existing investors.

The Company intends to use the net proceeds from the private placement to fund pre-commercial activities for its products and general corporate purposes, which will include the clinical development of its lead asset tegoprubart.

The securities sold in the private placement, including the common shares underlying the pre-funded warrants, are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws. Concurrently with the execution of the securities purchase agreement, Eledon and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the securities issued in the private placement.

Leerink Partners is acting as lead placement agent. LifeSci Capital and Noble Capital Markets are acting as co-placement agents in connection with the financing.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
Berry & Company Public Relations
(212) 253 8881
jurban@berrypr.com

Source: Eledon Pharmaceuticals

FAQ

What is the amount of the private placement deal announced by Eledon Pharmaceuticals?

Eledon Pharmaceuticals announced an oversubscribed $50 million private placement deal.

Who led the oversubscribed financing for Eledon Pharmaceuticals?

The oversubscribed financing was led by BVF Partners LP.

What is the purpose of the net proceeds from the private placement for Eledon Pharmaceuticals?

The net proceeds from the private placement will be used for pre-commercial activities for its products and general corporate purposes, including the clinical development of its lead asset tegoprubart.

When is the financing expected to close for Eledon Pharmaceuticals?

The financing is expected to close the week of May 6, 2024, subject to customary closing conditions.

Who are the lead and co-placement agents involved in the financing for Eledon Pharmaceuticals?

Leerink Partners is acting as lead placement agent, while LifeSci Capital and Noble Capital Markets are acting as co-placement agents in connection with the financing.